- Home
- GOSS vs AMBQ Comparison
GOSS vs AMBQ Comparison
Compare GOSS & AMBQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- AMBQ
- Stock Information
- Founded
- GOSS 2015
- AMBQ 2010
- Country
- GOSS United States
- AMBQ United States
- Employees
- GOSS N/A
- AMBQ N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- AMBQ Semiconductors
- Sector
- GOSS Health Care
- AMBQ Technology
- Exchange
- GOSS Nasdaq
- AMBQ Nasdaq
- Market Cap
- GOSS 586.6M
- AMBQ 673.1M
- IPO Year
- GOSS 2019
- AMBQ 2025
- Fundamental
- Price
- GOSS $3.08
- AMBQ $33.03
- Analyst Decision
- GOSS Strong Buy
- AMBQ Buy
- Analyst Count
- GOSS 6
- AMBQ 4
- Target Price
- GOSS $8.60
- AMBQ $43.75
- AVG Volume (30 Days)
- GOSS 4.8M
- AMBQ 204.5K
- Earning Date
- GOSS 11-06-2025
- AMBQ 11-14-2025
- Dividend Yield
- GOSS N/A
- AMBQ N/A
- EPS Growth
- GOSS N/A
- AMBQ N/A
- EPS
- GOSS N/A
- AMBQ N/A
- Revenue
- GOSS $40,237,000.00
- AMBQ $74,210,000.00
- Revenue This Year
- GOSS N/A
- AMBQ N/A
- Revenue Next Year
- GOSS $34.10
- AMBQ $25.34
- P/E Ratio
- GOSS N/A
- AMBQ N/A
- Revenue Growth
- GOSS N/A
- AMBQ N/A
- 52 Week Low
- GOSS $0.66
- AMBQ $31.60
- 52 Week High
- GOSS $3.60
- AMBQ $51.76
- Technical
- Relative Strength Index (RSI)
- GOSS 61.72
- AMBQ N/A
- Support Level
- GOSS $2.93
- AMBQ N/A
- Resistance Level
- GOSS $3.37
- AMBQ N/A
- Average True Range (ATR)
- GOSS 0.29
- AMBQ 0.00
- MACD
- GOSS 0.01
- AMBQ 0.00
- Stochastic Oscillator
- GOSS 57.55
- AMBQ 0.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.